Search research articles
Contact Us
Filters
Showing results (11-20 of 459) with videos related to
Page
of 46
Sort By:
The New England Journal of Medicine
|
March 6, 2018
Durvalumab in Stage III Non-Small-Cell Lung Cancer
Matteo Santoni, Nicola Battelli, Sebastiano Buti
Cellular & Molecular Immunology
|
June 3, 2014
Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients
Matteo Santoni, Francesco Massari, Stefano Cascinu
European Urology
|
May 14, 2024
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Martina Catalano, Matteo Santoni, Giandomenico Roviello
Expert Review of Anticancer Therapy
|
May 29, 2026
Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models
Kannan Sridharan, Gowri Sivaramakrishnan, Matteo Santoni
European Urology Oncology
|
June 16, 2019
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni
European Urology Oncology
|
July 7, 2019
New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
Cellular & Molecular Immunology
|
November 25, 2014
Altering macrophage polarization in the tumor environment: the role of response gene to complement 32
Matteo Santoni, Stefano Cascinu, Charles D Mills
European Urology
|
May 1, 2018
Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
The Lancet. Oncology
|
September 8, 2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
Expert Opinion on Biological Therapy
|
June 12, 2015
The immunocheckpoints in modern oncology: the next 15 years
Francesco Massari, Matteo Santoni, Chiara Ciccarese, et al.
Page
of 46
Search research articles
Search
Showing results (11-20 of 459) with videos related to
Sort By:
Page
of 46
The New England Journal of Medicine
|
March 6, 2018
Durvalumab in Stage III Non-Small-Cell Lung Cancer
Matteo Santoni, Nicola Battelli, Sebastiano Buti
Cellular & Molecular Immunology
|
June 3, 2014
Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients
Matteo Santoni, Francesco Massari, Stefano Cascinu
European Urology
|
May 14, 2024
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Martina Catalano, Matteo Santoni, Giandomenico Roviello
Expert Review of Anticancer Therapy
|
May 29, 2026
Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models
Kannan Sridharan, Gowri Sivaramakrishnan, Matteo Santoni
European Urology Oncology
|
June 16, 2019
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni
European Urology Oncology
|
July 7, 2019
New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
Cellular & Molecular Immunology
|
November 25, 2014
Altering macrophage polarization in the tumor environment: the role of response gene to complement 32
Matteo Santoni, Stefano Cascinu, Charles D Mills
European Urology
|
May 1, 2018
Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
The Lancet. Oncology
|
September 8, 2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
Vincenzo Di Nunno, Matteo Santoni, Francesco Massari
Expert Opinion on Biological Therapy
|
June 12, 2015
The immunocheckpoints in modern oncology: the next 15 years
Francesco Massari, Matteo Santoni, Chiara Ciccarese, et al.
Page
of 46